GLP-1 Savings Programs

Every major GLP-1 manufacturer offers some form of savings program, but the rules, caps, and eligibility criteria are not interchangeable. The wrong program at the wrong time can leave money on the table or — more commonly — produce false expectations about what your monthly cost will look like.

This guide walks through the three main categories that matter for patients in 2026: manufacturer savings cards (for patients with commercial insurance), self-pay pricing (for cash patients without coverage), and patient assistance programs (for low-income patients). Pricing and program terms change frequently — verify with the manufacturer or your pharmacy before you commit to a monthly schedule.

The three categories that matter

The savings landscape can feel cluttered, but most programs fall into one of three buckets:

Manufacturer savings cards are designed for patients who already have commercial health insurance that covers the medication. The card reduces your copay (often to $25 per month) up to a monthly and annual cap. Government insurance — Medicare, Medicaid, TRICARE, VA, DOD — is excluded by federal anti-kickback rules.

Self-pay programs are direct-to-consumer pricing from the manufacturer for patients without insurance coverage. These are not coupons layered on retail — they're separate channels (often the manufacturer's own mail-order pharmacy) that offer a fixed, lower monthly price. Eligibility usually requires that you not have government insurance and that you have a valid prescription.

Patient assistance programs are need-based foundations that provide medications at no cost or deeply reduced cost to qualifying patients. Eligibility is income-tested and documentation-heavy, and approvals are typically valid for a year before renewal.

How to use savings programs

Wegovy (semaglutide) — Novo Nordisk

The Wegovy Savings Offer is the manufacturer savings card. With commercial insurance that covers Wegovy, eligible patients can pay as little as $25 per month, subject to a maximum savings of roughly $100 per 1-month fill, $200 per 2-month fill, and $300 per 3-month fill. Card usage is restricted to patients with commercial drug insurance and excludes government insurance.

The NovoCare Pharmacy self-pay program is the cash-pay path. Through Novo Nordisk's direct-to-consumer pharmacy, self-paying patients can currently access Wegovy at roughly $349 per month across all dose strengths. Introductory pricing for new patients on lower starting doses has been around $199 per month, though specifics and end dates evolve — confirm current rates before enrolling. The program requires no government insurance and a valid prescription sent electronically to NovoCare Pharmacy.

Novo Nordisk also runs a Patient Assistance Program for qualifying patients with limited income who lack insurance coverage. Eligibility is income-tested with documentation requirements.

Zepbound (tirzepatide) — Eli Lilly

The Zepbound Savings Card is the manufacturer copay program. With commercial insurance that covers Zepbound's single-dose pen, eligible patients can pay as little as $25 per month, with a maximum monthly savings of roughly $100 per 1-month fill, $200 per 2-month fill, or $300 per 3-month fill, and a separate maximum annual savings of roughly $1,300 per calendar year. Government insurance is excluded.

The LillyDirect Self-Pay Journey Program offers single-dose vials at fixed monthly prices — currently around $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg. Available exclusively through LillyDirect Pharmacy. The vial format requires drawing each dose into a syringe rather than using a pre-filled pen.

The Lilly Cares Foundation provides medications at no cost to qualifying low-income patients without insurance. Eligibility is income-tested with annual renewal.

Saxenda and Victoza (liraglutide) — Novo Nordisk

Older GLP-1 medications like liraglutide-based Saxenda and Victoza have historically had Novo Nordisk savings cards and patient assistance available, though the dollar amounts and program structures differ from the newer Wegovy and Zepbound programs. Generic liraglutide also began arriving in 2024, which has reshaped the cash-pay landscape for this molecule. If you're being prescribed liraglutide, ask your pharmacy about both the brand savings program and the generic option's cash price.

Ozempic and Mounjaro: a different conversation

Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not chronic weight management. Manufacturer savings programs exist for these drugs but typically require a diabetes diagnosis to maintain insurance coverage, and the savings card terms are slightly different from the weight-management labels. If you're being prescribed one of these for diabetes, check the program specific to the diabetes label rather than the weight-management programs described above.

Medicare and the GLP-1 Bridge

Manufacturer savings cards exclude Medicare beneficiaries by design. For most of the history of these drugs, Medicare Part D has also excluded anti-obesity medications outright.

That changes — for a limited window — with CMS's Medicare GLP-1 Bridge demonstration program. From July 1, 2026 through December 31, 2027, eligible Part D beneficiaries can access Wegovy (all formulations), Zepbound's KwikPen formulation, and Foundayo at roughly $50 per month. Eligibility generally requires BMI of 27 or higher with a qualifying condition such as cardiovascular disease or prediabetes, or BMI of 35 or higher. The $50 copay does not count toward the Part D deductible or the annual out-of-pocket cap. Program details may change — confirm with CMS and your Part D plan before relying on this path.

Picking the right program

The decision usually walks down a short list of questions. Do you have commercial insurance that covers the drug? If yes, the manufacturer savings card is almost always the right path. Do you have no insurance or a plan that excludes anti-obesity medications? If yes, the manufacturer self-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) are typically your lowest direct cost. Is your income low enough that you can't afford even the self-pay program? If yes, patient assistance programs are worth applying to, recognizing that approval takes time and requires documentation.

Are you on Medicare? Until July 1, 2026, traditional Part D didn't cover anti-obesity drugs and manufacturer savings cards exclude Medicare beneficiaries. Starting that date, the GLP-1 Bridge demonstration becomes the relevant path for eligible beneficiaries through the end of 2027.

Common questions

Keep exploring

Browse all GLP-1 guides.